Chemotherapy in pancreatic ductal adenocarcinoma: when cytoreduction is the aim. A systematic review and meta-analysis
According to GLOBOCAN 2020, pancreatic cancer is currently the 7th most common fatal cancer worldwide [1]. However, in some regions as Europe and North America, it represents the 4th most common cause of cancer death [2,3]. Pancreatic adenocarcinoma (PDAC) accounts for 80% of all pancreatic cancers. [4] It is a neoplasm with poor prognosis, even for early stages. The 5-year relative survival is 41.5% for patients with localized disease, 14.4% for regional disease and 3% for those with metastatic disease [5 –7].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Monica I. Meneses-Medina, Lorenzo Gervaso, Chiara A. Cella, Stefania Pellicori, Sara Gandini, Maria J. Sousa, Nicola Fazio Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Men | Pancreas | Pancreatic Cancer